Publication number: 20260176289
Abstract: Compounds of Formula (I) or their pharmaceutically acceptable salts can inhibit the G12C, G12D, G12V, and/or G13D mutants of Kirsten rat sarcoma (KRAS) protein and are expected to have utility as therapeutic agents, for example, for treating cancer. The disclosure also provides pharmaceutical compositions which comprise compounds of Formula (I) or pharmaceutically acceptable salts thereof. The disclosure also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of cancer and for preparing pharmaceuticals for this purpose.
Type:
Application
Filed:
November 10, 2023
Publication date:
June 25, 2026
Inventors:
Symon Gathiaka, Shuhei Kawamura, Matthew J. Mitcheltree, Anandan Palani, Juan del Pozo, Uma Swaminathan, Hua Zhou, Yu Kobayakawa, Satoru Iguchi, Hitomi Kondo, Keiichi Sumiyama, Patrick Schöpf, Steven Howard, George Madalin Giambasu, Melanie A. S. Blackburn, Solomon Kattar, Igri Kolaj, Bing Li, Michael Ryan, Emily Ruan, Tobias Sandmeier, David L. Sloman, Tomohiro Yamamoto, Makoto Kitade, Junpei Koyama, Tsuyoshi Oshima, Kei Akemoto, Toshihiro Sakamoto, Hiroki Asakura, Risako Miura